## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : 10/684,149

James W. West, Cameron S. Brandt, Stephen R. Jaspers

Serial No

Filed : October 10, 2003

For : PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS

Confirmation No.: 5157

Examiner : Schwadron, R. B.

Art Unit · 1644

Docket No. : 02-17 Date : October 11, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Restriction Requirement mailed September 15, 2006, has been received and reviewed

The Office Action sets forth a restriction requirement under 35 USC §121. Applicants were requested to elect one of four (4) designated groups as briefly noted below:

- T. Claims 1-11, drawn to a polypeptide, classified in class 530, subclass 402.
- Π. Claims 12 and 13, drawn to ectors and host cells, classified in class 435, subclasses 325 and 320.1.
- Ш. Claim 14, drawn to a method of making a polypeptde, classified in class 435, subclass 69.7.
- Claims 15-17, drawn to a method of inhibiting B cell proliferation, classified in class 514, subclass 2.

Response to Restriction Requirement dated:

In response to the Requirement for Restriction Election, Applicants elect Group I, claims 1-11, drawn to a polypeptide, classified in class 530, subclass 402.

The Office Action sets forth a further species restriction requirement. Applicants were requested to elect (a) one extracellular domain from the group consisting of (1) amino acid residues 30 to 110 of SEQ ID NO:4, (2) amino acid residues 1 to 110 of SEQ ID NO:4, (3) amino acid residues 30 to 154 of SEO ID NO:4, and (4) amino acid residues 1 to 154 of SEO ID NO:4; and (b) one trimerizing polypeptide from the group consisting of (1) the NC-1 fragment of human collagen X and (1) a trimerizing fragment of Heat Shock Binding Protein-1.

In response to the Requirement for Species Election, Applicants elect (a) the extracellular domain of (1) amino acid residues 30 to 110 of SEQ ID NO:4 and (b) the trimerizing polypeptide of the NC-1 fragment of human collagen X.

It is believed that no fee is due. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Early reconsideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6627.

Respectfully Su

ifer K. Johnson, J.D. Registration No. 43,696

Customer No. 10117 ZymoGenetics, Inc.